Avanish Mishra

Avanish Mishra

Auto-generated profile, based on publicly available information

Avanish Mishra

Center for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2026 in Cancer Discovery
Verified
Journal Article
Open access
AMAvanish Mishra
Avanish Mishra
CMCatherine B. Meador
Catherine B. Meador
KKKruthika Kikkeri
Kruthika Kikkeri
QCQuinn Cunneely
Quinn Cunneely
MLMaoxuan Lin
Maoxuan Lin
DHDaniel A. Haber
Daniel A. Haber
The bispecific antibody tarlatamab recruits T cells to cancers expressing the neuroendocrine epitope delta-like ligand 3 (DLL3). Tarlatamab is effective in small cell lung cancer (SCLC), but clinical outcomes vary, and no biomarkers enable patient selection. Single-cell RNA sequencing of SCLC biopsies identifies heterogeneity in DLL3 expression, and analysis of circulating tumor cells (CTC) distinguishes individual patients as predominantly DLL3Pos or DLL3Low. In a prospective cohort of 20 patients, pretreatment DLL3 expression on CTCs predicts tarlatamab clinical benefit (85% sensitivity and 100% specificity). Necrotic CTC clusters in blood accompany treatment-induced tumor lysis. Acquired resistance to tarlatamab is associated in some cases with loss of DLL3 expression but persistence of other targetable neuroendocrine epitopes; in other patients, DLL3 is retained on CTCs but accompanied by systemic markers of T-cell dysfunction. Quantitation of DLL3-positive CTCs identifies patients likely to benefit from tarlatamab, and longitudinal monitoring may guide therapeutic decision-making at the time of acquired resistance. Significance: CTCs are abundant in SCLC, allowing noninvasive quantitation of epitopes targeted by immune therapies. Patients with at least 25% DLL3-positive CTCs derive clinical benefit from a bispecific antibody targeting this epitope; those with a lower fraction rarely respond. CTC scoring may thus enable stratification of patients for antibody-mediated therapeutics.

2 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
KGKaustav Aras Gopinathan
Kaustav Aras Gopinathan
AMAvanish Mishra
Avanish Mishra
BMBaris Ragip Mutlu
Baris Ragip Mutlu
JFJon F.
Jon F.
MTMehmet Toner
Mehmet Toner
/Summary: Microfluidics have enabled significant advances in molecular biology 1–3 , synthetic chemistry 4,5 , diagnostics 6,7 , and tissue engineering 8 . However, there has long been a critical need in the field to manipulate fluids and suspended matter with the precision, modularity, and scalability of electronic circuits 9–11 . Just as the electronic transistor enabled unprecedented advances in the control of electricity on an electronic chip, a microfluidic analogue to the transistor could enable improvements in the complex, scalable control of reagents, droplets, and single cells on an autonomous microfluidic chip. Prior works on creating a microfluidic analogue to the electronic transistor 12–14 could not replicate the transistor’s saturation behavior, which is crucial to perform analog amplification 15 and is fundamental to modern circuit design 16 . Here we exploit the fluidic phenomenon of flow-limitation 17 to develop a microfluidic element with flow-pressure characteristics completely analogous to the current-voltage characteristics of the electronic transistor. As this microfluidic transistor successfully replicates all of the key operating regimes of the electronic transistor (linear, cut-off and saturation), we are able to directly translate a variety of fundamental electronic circuit designs into the fluidic domain, including the amplifier, regulator, level shifter, logic gate, and latch. Finally, we demonstrate a “smart” particle dispenser that senses single suspended particles, performs liquid signal processing, and accordingly controls the movement of said particles in a purely fluidic system without electronics. By leveraging the vast repertoire of electronic circuit design, microfluidic transistor-based circuits are easy to integrate at scale, eliminate the need for external flow control, and enable uniquely complex liquid signal processing and single-particle manipulation for the next generation of chemical, biological, and clinical platforms.

31 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MRMaheen Rana
Maheen Rana
SNSophia E. Nigrovic
Sophia E. Nigrovic
APAdriana Payan-Medina
Adriana Payan-Medina
SSSarthak Saha
Sarthak Saha
VPVictor R. Putaturo
Victor R. Putaturo
AMAvanish Mishra
Avanish Mishra
Treatment with chimeric antigen receptor (CAR) T cells has emerged as a promising immune therapy for relapsed and refractory hematologic malignancies. The CAR T cells are manufactured in a series of steps that involve isolating T cells from the patient’s leukapheresis product, genetically modifying them to express the CAR against the target antigen, and reinfusing them into the patient. Efficient T-cell enrichment from leukapheresis products is critical to the success of these therapies. Current methods for T-cell sorting on a clinical scale involve several washing steps to remove red blood cells and platelets, followed by T-cell selection and activation. These multi-step processes result in cell loss during processing and involve several handling steps. Here, we utilize fluidically assembled micromagnetic lenses to develop a high-throughput, continuous-flow microfluidic T-cell sorter, designated as the T-Chip, for sorting magnetic bead-labeled CD3 + T cells in a single step. Our approach allows direct sorting of T cells in expansion media from leukopaks without any washing steps, effectively removing 99.999% of RBCs and platelets from the leukapheresis product. A single 1-inch x 3-inch T-Chip can process leukapheresis product at a throughput of 60 mL/hr and 2.56 ± 0.12 billion cells/hr. Using this optimized workflow, we demonstrate clinical-scale enrichment of highly pure CD3 + T cells (97.7 ± 1.3%) with high viability (97.0 ± 1.1%) and recovery (87.3 ± 14.8%) in a functionally closed manner. Downstream processing of T cells isolated using the T-Chip yielded potent anti-mesothelin CAR T cells with demonstrated anti-tumor efficacy. Overall, by exploiting precisely engineered magnetic forces and laminar flow, the microfluidic T-Chip overcomes bottlenecks caused by low throughput and enables single-step large-scale T-cell purification for the rapid development of CAR T cells.

18 June 2026
Verified
Other
Open access
AMAvanish Mishra
Avanish Mishra
CMCatherine B. Meador
Catherine B. Meador
KKKruthika Kikkeri
Kruthika Kikkeri
QCQuinn Cunneely
Quinn Cunneely
MLMaoxuan Lin
Maoxuan Lin
DHDaniel A. Haber
Daniel A. Haber
Supplementary Figure 7 shows CNV of SCLC tumor biopsies for patient-2.

18 June 2026
Verified
Other
Open access
AMAvanish Mishra
Avanish Mishra
CMCatherine B. Meador
Catherine B. Meador
KKKruthika Kikkeri
Kruthika Kikkeri
QCQuinn Cunneely
Quinn Cunneely
MLMaoxuan Lin
Maoxuan Lin
DHDaniel A. Haber
Daniel A. Haber
Supplementary Table S2 shows the exclusion criteria for analysis cohort.

18 June 2026
Verified
Other
Open access
PDF file
AMAvanish Mishra
Avanish Mishra
CMCatherine B. Meador
Catherine B. Meador
KKKruthika Kikkeri
Kruthika Kikkeri
QCQuinn Cunneely
Quinn Cunneely
MLMaoxuan Lin
Maoxuan Lin
DHDaniel A. Haber
Daniel A. Haber
Supplementary Figure S16 shows CD4+ T cells phenotypic profiling for individual markers in control sample HD2.